Journavx is one of 131 small molecule programs targeting Rib Fracture. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
275 competitors in Total Knee Arthroplasty
Journavx
Cymbalta
Lyrica
Xarelto
Precedex
Sufenta
EXPAREL
Nucynta
Xylocaine
Epsom Salt
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 30, 2025
JOURNAVX
NDA NDA219209
Sources
Details
Patent Cliff
Dec 4, 2040
Earliest patent expiration — generic entry possible after this date